FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome

The U.S. FDA has placed a clinical hold on Regenxbio's experimental gene therapy RGX-121 for Hunter syndrome after abnormalities were found in spinal scans of five study participants. Regenxbio does not expect to resubmit its application for approval soon.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.